XML 83 R39.htm IDEA: XBRL DOCUMENT
v3.22.4

Other operating expenses | 12 Months Ended
--- | ---
Dec. 31, 2022
Analysis of income and expense [abstract] |
Other operating expenses | Other operating expenses Other operating expenses totaled €2,531 million in 2022, compared with €1,805 million in 2021 and €1,415 million in 2020. For 2022, this line item includes €2,378 million of expenses relating to the alliance with Regeneron (see Note C.1.), compared with €1,568 million for 2021 and €1,090 million for 2020 (as shown in the table below):
(€ million) | 2022 | 2021 | 2020
Income & expense related to sharing of (profits)/losses under the Monoclonal Antibody Alliance | (2,325) |  | (1,253) |  | (727) |
Additional share of profit paid by Regeneron towards development costs (b) | 434 |  | 127 |  | 75 |
Reimbursement to Regeneron of selling expenses incurred | (476) |  | (303) |  | (349) |
Total - Monoclonal Antibody Alliance | (2,367) |  | (1,429) |  | (1,001) |
Immuno-Oncology Alliance | 16 |  | 68 |  | 89 |
Other (mainly Zaltrap® and Libtayo®)(a) | 1,120 |  | (12) |  | (14) |
Other operating income/(expenses), net related to the Regeneron Alliance | (1,231) |  | (1,373) |  | (926) |
of which amount presented in Other operating income (Note D.25.) | 1,147 |  | 195 |  | 164 |
(a) Following the restructuring of the Immuno-Oncology agreement between Sanofi and Regeneron, applicable from July 1, 2022 (see Note C.1.). (b) As of December 31, 2022, the commitment received by Sanofi in respect of the additional profit share payable by Regeneron towards development costs amounted to €2.7 billion, compared with €2.9 billion as of December 31, 2021 (see note D.21). Charges to provisions for litigation and environmental risks are also recorded within this line item.

X
- References No definition available. + Details
Name: | ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of other operating expense. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration